# Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

> **NCT06136546** · PHASE2 · RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Depressive Disorder, Major
- Inflammation

## Interventions

- **DRUG:** Infliximab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06136546
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-23
- **Primary completion:** 2028-08-31
- **Final completion:** 2029-01-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06136546

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06136546, "Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06136546. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*